Amgen's trebananib down, not out in ovarian cancer
This article was originally published in Scrip
Executive Summary
Trebananib did not significantly improve overall survival for women with recurrent ovarian cancer, a secondary endpoint of the TRINOVA-1 trial, but Amgen has two more Phase III opportunities to show a meaningful improvement for patients with the difficult cancer.
You may also be interested in...
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.